Abstracts tagged "clinical trials and lupus nephritis"

Abstract Number: 971 • 2018 ACR/ARHP Annual Meeting
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept or Placebo on Standard of Care in Patients with Active Class III or IV Lupus Nephritis
Mary A. Dooley¹, Gerald B. Appel², Richard Furie³, David Wofsy⁴, Tsutomu Takeuchi⁵, Ana Malvar⁶, Andrea Doria⁷, Juanita Romero-Díaz⁸, Tak Mao Chan⁹, Ayanbola Elegbe¹⁰, David Jayne¹¹ and Michael A. Maldonado¹⁰, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Columbia University Medical Center, New York, NY, ³Northwell Health, New York, NY, ⁴University of California San Francisco, San Francisco, CA, ⁵Keio University School of Medicine, Tokyo, Japan, ⁶Nephrology Division, Hospital Fernández, Buenos Aires, Argentina, ⁷Division of Rheumatology, University of Padova, Padova, Italy, ⁸Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico, ⁹University of Hong Kong, Hong Kong, Hong Kong, ¹⁰Bristol-Myers Squibb, Princeton, NJ, ¹¹University of Cambridge, Cambridge, United Kingdom
Background/Purpose: The tenets of novel treatment (tx) strategies for active class III/IV lupus nephritis (LN) aim to improve renal response rates, decrease extra-renal SLE disease…
Abstract Number: 1870 • 2018 ACR/ARHP Annual Meeting
Phase 2 Trial of Induction Therapy with Anti-CD20 (Rituximab) Followed By Maintenance Therapy with Anti-BAFF (Belimumab) in Patients with Active Lupus Nephritis
Maria Dall'Era¹, Cynthia Aranow², Margaret Byron³, Linna Ding⁴, Dawn Smilek⁵, Betty Diamond⁶ and David Wofsy⁷, ¹University of California, San Francisco, San Francisco, CA, ²The Feinstein Institute for Medical Research, Manhasset, NY, ³Rho Federal Systems, Inc., Chapel Hill, NC, ⁴National Institute of Allergy and Infectious Diseases, Bethesda, MD, ⁵Immune Tolerance Network, San Francisco, CA, ⁶Autoimmune Musculoskeletal and Hematopoietic Diseases, The Feinstein Institute for Medical Research, Manhasset, NY, ⁷Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Two randomized, controlled trials of rituximab in patients with lupus and lupus nephritis (LN) did not meet their primary endpoints. A potential explanation is…